维普期刊资源整合服务平台（V6.5）

57篇 您的检索式：作者名="Erlichman C"

选中清除导出查看参考文献查看引证文献引用追踪共3页首页上一页第1页下一页末页 /3 跳转

	题名	作者	年代	出处	被引量
1	A phase Ⅰ and pharmacokinetic study of temsirolimus (CCI-779) administered intravenously daily for 5 days every 2 weeks to patients with advanced cancer显示文摘	HIDALGO M BUCKNER JC ERLICHMAN C	2006	Clln Cancer Res2006，12，19：	1
2	A phase Ⅰ trial of the farnesyl transferase inhibitor SCH66336: evidence for biological and clinical activity 显示文摘	Erlichman C Davis JN	2000	Cancer Res2000，60，：	1
3	Phase Ⅰ study of EKB-569,an irreversible inhibitor of the epidermal growth factor receptor,in patients with advanced solid tumors显示文摘	Erlichman C Hidalgo M Boni JP	2006	J Clin Oncol2006，24，15：	1
4	A phase I and pharmacokinetic study of temsirolimus (CCI-779) administered intravenously daily for 5 days every 2 weeks to patients with advanced cancer显示文摘	Hidalgo M Buckner JC Erlichman C	2006	Clin Cancer Res2006，12，19：	1
5	The HER tyrosine kinase inhibitor CI-1033 enhances cytotoxicity of 7-ethyl-10-hydroxycamptothecin and topotecan by inhibiting breast cancer resistance protein-mediated drug efflux显示文摘	Erlichman C Boerner S A Hallgren C G	2001	Cancer Res2001，61，1：	1
6	Phase I pharmacokinetic and pharmacodynamic study of a new anthrapyrazole,Ci 937 (Dup937)显示文摘	Erlichman C Moore M Kerr IG	1991	Cancer Res1991，51，23：	1
7	A phase I and pharmacokinetic study of the selective, non-peptidic inhibitor of matrix metalloproteinase BAY 12-9566 in combination with etoposide and carboplatin 显示文摘	Molina JR Reid JM Erlichman C	2005	Anti- cancer Drugs2005，16，：	1
8	Male breast cancer:all-year review of 66 patients显示文摘	Mclachlan SA Erlichman C Liu FF	1996	Breast Cancer Res Treat1996，40，3：	1
9	Molecular markers in male breast cancer显示文摘	Erlichman C SumanVJ	1998	Cancer1998，83，9：	1
10	A randomized trial of fluorouracil and folinic acid in patients with metastatic colorectal cacinoma显示文摘	Erlichman C Fine S Wong A	1988	J Clin Oncol1988，6，3：	1
11	Molecular markers in male breast carcinoma显示文摘	Rayson D Erlichman C Suman VJ	1998	Cancer1998，83，9：	1
12	A phase I trial of ISIS 2503,an antisense inhibitor of H-ras, in combination with gemcitabine in patients with advanced cancer显示文摘	Adjei AA Dy GK Erlichman C	2003	Clin Cancer Res2003，9，1：	1
13	Gemcitabine and I-SIS-2503 for patients with locally advanced or metastatic pancreaticadenocarcinoma:a north central cancer treatment group phase IItrial显示文摘	Alberts S R Schroeder M Erlichman C	2004	J Clin Oncol2004，22，24：	1
14	Phase Ⅰ study of EKB - 569, an irreversible inhibitor of the epidermal growth factor receptor, in patients with advanced solid tumors显示文摘	Erlichman C Hidalgo M Boni JP	2006	J Clin Oncol2006，24，15：	1
15	Adjuvant therapy of colon cancer:a review显示文摘	Erlichman C	2002	Clin Colorectal Cancer2002，1，4：	1
16	Disposition of total and free cisplatin on two consecutive treatment cycles in patients with ovarian cancer 显示文摘	Erlichman C Soldin S J Thiessen J J	1987	Cancer Chemother Pharmacol1987，19，1：	1
17	Male breast cancer:an 11year review of 66 patients显示文摘	Mc Lachlan SA Erlichman C Liu FF	1996	Breast Cancer Res Treat1996，40，3：	1
18	Male breast Cancer: a 11 yearreview of 66 patients 显示文摘	Mclaclan SA Erlichman C Liu FF	1996	Breast Cancer Res Treat1996，40，3：	1
19	The HER tyrosine Kinase inhibitor CI1033 enhances cytotoxicity of 7-ethyl-10-hydroxycamptothecin and topotecan by inhibiting breast cancer resistance protein-mediated drug efflux显示文摘	Erlichman C Boerner SA Hallgren CG	2001	Cancer Res2001，61，2：	1
20	Male breast cancer:all-year review of 66 patients显示文摘	Mclachlan SA Erlichman C Liu FF	1996	Breast Cancer Res Treat1996，40，3：	1

返回顶部每页显示：

共3页首页上一页第1页下一页末页 /3 跳转

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

用户提示